Monitor future 10-Q and 10-K filings for disclosure of actual shares sold under this ATM facility, which will indicate the extent of dilution and capital raised.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 16 $0.6421entry
- T+1 · 11h ago −0.28%α +0.73% · $0.6403
- T+5 · in 6d Pending
- T+20 · in 28d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
DataMEDS AI, Inc. entered into an ATM sales agreement with Dawson James Securities to sell up to $10,003,649 of its common stock from time to time in at-the-market offerings. The company is not obligated to sell any shares, and the agreement provides a 3.0% commission to the sales agent. This establishes a potential equity dilution facility but no shares have been sold yet.
Key Facts
- DataMEDS AI, Inc. entered into an ATM sales agreement with Dawson James Securities on November 16, 2026
- Maximum offering amount is $10,003,649 of common stock
- Sales agent receives 3.0% commission on gross proceeds from each sale
- Company is not obligated to sell any shares under the agreement
- Shares sold through at-the-market offerings on Nasdaq or other methods
- Registration statement on Form S-3 (File No. 333-295078) was declared effective on May 7, 2026
Financial Impact
Up to $10,003,649 in potential gross proceeds from common stock sales, with 3.0% commission to the sales agent
Risk Factors
- Potential dilution if shares are sold into the market
- No guarantee of capital raise; the facility may remain unused
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-051924 |
| Exhibit: ex5-1.htm | 0001493152-26-051924 |
| Document: form8-k.htm | 0001493152-26-051924 |
| Document: 0001493152-26-051924-index-headers.html | 0001493152-26-051924 |
| Document: 0001493152-26-051924-index.html | 0001493152-26-051924 |
| Document: 0001493152-26-051924.txt | 0001493152-26-051924 |
Track record
15 reports on MEDS
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +35.05% at T+60 after the Aug 18, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 17, 2026today 424B5 Bearish 6/10 Entry price pending
- Nov 17, 2026today 8-K Bearish 7/10 Entry $0.6151 Now $0.6403 −4.10% settles Nov 25
- Nov 16, 20261d ago 424B5 Bearish 5/10 Entry $0.6421 Now $0.6403 +0.28% settles Nov 23
- Nov 16, 20261d ago 8-K Neutral 3/10 Viewing Entry $0.6421 Now $0.6403 −0.28% settles Nov 23
- Nov 13, 20264d ago 8-K Neutral 5/10 Entry $0.6421 Now $0.6403 −0.28% settles Nov 23
- Nov 10, 20266d ago SC 13G Neutral 4/10 Entry $0.9531 Now $0.6403 −32.82% settles Nov 18
- Nov 10, 20267d ago S-1/A Bearish 6/10 Entry $0.9531 Now $0.6403 +32.82% settles Nov 18
- Nov 5, 202612d ago 8-K Neutral 4/10 Entry $1.22 to $0.8702 Now $0.6403 −47.52% ▼ −28.67% −31.96% vs SPY
- Oct 26, 202622d ago 8-K Bearish 6/10 Entry $2.06 to $1.80 Now $0.6403 +68.92% ▲ +12.62% +10.63% vs SPY
- Oct 20, 202628d ago 8-K Neutral 4/10 Entry $2.75 to $2.06 Now $0.6403 −76.72% ▼ −25.09% −25.17% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers